

PCT

IP3 Rec'd PCT/PTO 06 MAR 2006

AstraZeneca



IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Application No.: 10/549460	Applicant: DAHL, Niklas
371 Filing Date: September 16, 2005	Attorney Docket No.: 100852-1US
Examiner: Not Yet Assigned	Group Art Unit : Not yet Assigned
Customer No.: 44992	Confirmation No.: Not yet Assigned
Title: GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 1, 2006

Signature
Janine Proctor

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:
before the mailing of the **first Office Action** on the merits, and therefore no fee is believe due.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100852-1P US.


Respectfully submitted,



Name: Lucy Padget
Dated: March 1, 2006
Phone No.: +1 781-839-4182
Reg No.: L0074

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Form SB08B (1 sheet – 13 documents)
Return Receipt Postcard



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/549460

Filing Date September 16, 2005

First Named Inventor DAHL, Niklas

Art Unit Not Yet Assigned

Examiner Name Not yet assigned

Attorney Docket No. 100852-1P US

SHEET 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	AHIMA ET AL, Leptin Regulation of Neuroendocrine Systems, <i>Frontiers in Neuroendocrinology</i> 21, pp. 263-307, 2000, vol. 21(3), Academic Press.	<input type="checkbox"/>
	AB	CLEMENT ET AL, The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes, <i>International Journal of Obesity</i> , 2000, pp. 391 – 393, vol. 24 (3), Macmillan Publishers Ltd.	<input type="checkbox"/>
	AC	FRIEDMAN & HALAAS, Leptin and the regulation of body weight in mammals, 1998, pp. 763 – 770, <i>Nature</i> vol. 395. Macmillan Publishers Ltd.	<input type="checkbox"/>
	AD	HEDGECOCK ET AL, The unc-5, unc-6 and unc-40 genes guide circumferential migrations of pioneer axons and mesodermal cells on the epidermis in <i>C. elegans</i> , 1990, pp. 61 – 85, <i>Neuron</i> vol. 4 (1), Cell Press.	<input type="checkbox"/>
	AE	JANKNECHT ET AL, Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus, 1991, pp. 8972 – 8976, <i>Proc Natl Acad Sci</i> vol. 88.	<input type="checkbox"/>
	AF	KELEMAN & DICKSON, Short- and long- range repulsion by the drosophila Unc5 netrin receptor, 2001, pp. 605 – 617, <i>Neuron</i> vol. 32 (4), Cell Press.	<input type="checkbox"/>
	AG	LEUNG-HAGENSTEIJN ET AL, UNC-5, a transmembrane protein with immunoglobulin and thrombospondin type 1 domains, guides cell and pioneer axon migrations in <i>C. elegans</i> , 1992, pp. 289 – 299, <i>Cell</i> vol. 71 (2), Cell Press.	<input type="checkbox"/>
	AH	LEONARDO ET AL, Vertebrate homologues of <i>C. elegans</i> UNC-5 are candidate netrin receptors, 1997, pp. 833 – 838, <i>Nature</i> vol. 386.	<input type="checkbox"/>
	AI	VISSCHER & SEIDELL, The Public Health Impact of Obesity, <i>Annual Rev Public Health</i> , 2001, pp. 355-375, vol. 22 (1).	<input type="checkbox"/>
	AJ	WADSWORTH, Moving around in a worm: netrin UNC-6 and circumferential axon guidance in <i>C. elegans</i> , 2002, pp. 423 – 429, <i>Trends in Neurosciences</i> vol. 25 (8).	<input type="checkbox"/>
	AK	WITTUNG, DNA-like double helix formed by peptide nucleic acid, 1994, pp.561-563, <i>Nature</i> vol. 368, Nature Publishing Group.	<input type="checkbox"/>
	AL	YEO ET AL, A frameshift mutation in MC4R associated with dominantly inherited human obesity, 1998, pp. 111 – 112, <i>Nature Genetics</i> vol. 20 (2), Nature America Inc.	<input type="checkbox"/>
	AM	ZERVOS ET AL, Mxi1, a protein that specifically interacts with max to bid Myc-Max recognition sites, 1993, pp. 223 – 232, <i>Cell</i> vol. 72, Cell Press	<input type="checkbox"/>
Examiner Signature			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.